Hostname: page-component-6766d58669-r8qmj Total loading time: 0 Render date: 2026-05-23T08:30:12.045Z Has data issue: false hasContentIssue false
  • English
  • Français

Alternating cisplatinum and VAC ineffective in end stage squamous cell carcinoma of the head and neck

Published online by Cambridge University Press:  29 June 2007

M. Z. Siodlak ,
P. M. Stell ,
J. A. Wilson ,
J. A. Green ,
R. S. Allison ,
D. Adler  and
M. Squadrelli-Saraceno
M. Z. Siodlak
Affiliation:
(Liverpool)
P. M. Stell*
Affiliation:
(Liverpool)
J. A. Wilson
Affiliation:
(Liverpool)
J. A. Green
Affiliation:
(Liverpool)
R. S. Allison
Affiliation:
(Liverpool)
D. Adler
Affiliation:
(Liverpool)
M. Squadrelli-Saraceno
Affiliation:
(Liverpool)
*
Prof. P. M. Stell, Royal Liverpool Hospital, Prescot Street, P.O. Box 147, Liverpool L69 3BX
Get access Rights & Permissions [Opens in a new window]

Abstract

Sixteen patients with end stage squamous cell carcinoma of the head and neck were admitted to a phase II study of alternating courses of cisplatinum (100mg/m2) and VAC (vincristine 1.4mg/m2, adriamycin 50 mg/m2, cyclophosphamide 750 mg/m2) given at three weekly intervals. Only two patients achieved a response (12 per cent). The median survival time was 62 days which is much the same as that of a similar group of patients who received no chemotherapy in a previous trial (70 days).

Information

Type
Research Article
Information
The Journal of Laryngology & Otology , Volume 104 , Issue 8 , August 1990 , pp. 631 - 633
Copyright
Copyright © JLO (1984) Limited 1990

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Bitran, J. D., Goldman, M. (1985) A phase II trial of cyclophosphamide and adriamycin in refractory squamous cell carcinoma of the head and neck. An effective salvage regimen. American Journal of Clinical Oncology, 8: 61–64.CrossRefGoogle ScholarPubMed
Decker, D. A., Drelichman, A., Jacobs, J., Hoschner, J., Kinzie, J., Loh, J., Wever, A., Al-Sarraf, M. (1983) Adjuvant chemotherapy with cisdiamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neck. Cancer, 51: 1353–1355.3.0.CO;2-I>CrossRefGoogle ScholarPubMed
Feld, R., Evans, W. K., Coy, P., Hodson, I., MacDonald, A. S., Osoba, D., Payne, D., Shelley, W., Pater, J. L. (1987) Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. Journal of Clinical Oncology, 5: 1401–1409.CrossRefGoogle ScholarPubMed
Goldie, J. H., Coldman, A. J. (1979) A mathematical model for relating the drug sensitivity of tumours to the spontaneous mutation rate. Cancer Treatment Reports, 63: 1727–1733.Google Scholar
Goldie, J. H., Coldman, A. J., Gudauskas, G. A. (1982) Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treatment Reports, 66: 439–449.Google ScholarPubMed
Goodman, G. E., Crowley, J. J., Blasko, J. C., Livingston, R. B., Beck, T. M., Demattia, M. D., Bukowski, R. M. (1990) Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study. Journal of Clinical Oncology, 8: 39–47.CrossRefGoogle ScholarPubMed
Hong, W. K., Schaefer, S., Issell, B., Cummings, C., Luede, D., Bromer, R., Fofonoff, S., D'Aoust, J., Shapshay, S., Welch, J., Levin, E., Vincent, M., Vaughan, C., Strong, S. (1983) A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer, 52: 206–210.3.0.CO;2-J>CrossRefGoogle ScholarPubMed
Johnson, J. T., Mayernick, D. G., Myers, E. N., Nolan, T. A., Schramm, V. L., Sigler, B. S., Wagner, R. L. (1987) Cisplatin-5-fluorouracil chemotherapy for advanced inoperable squamous carcinoma of the head and neck. Head and Neck Surgery, 9: 336–340.CrossRefGoogle ScholarPubMed
Kartner, N., Ling, V. (1989) Multidrug resistance in cancer. Scientific American March, 26–33.Google ScholarPubMed
Miller, A. B., Hoogstraten, B., Staquet, M., Winkler, A. (1981) Reporting results of cancer treatment. Cancer, 47: 207–214.3.0.CO;2-6>CrossRefGoogle ScholarPubMed
Morton, R. P., Rugman, F., Dorman, E. B., Stoney, P. J., Wilson, J. A., McCormick, M. A., Veevers, A., Stell, P. M. (1985) Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomized factorial phase III controlled trial. Cancer Chemotherapy and Pharmacology, 15: 283–289.CrossRefGoogle ScholarPubMed
The Liverpool Head and Neck Oncology Group (1990) A phase III randomized trial of cisplatinum, methotrexate, cisplatinum + methotrexate, and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. British Journal of Cancer, 61: 311–315.CrossRefGoogle Scholar